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Abstract
Introduction: Candida species are major causes of healthcare-associated infections with colonization preceding
infection. Understanding risk factors for colonization by Candida species is important in prevention. However, data
on risk factors for colonization by Candida species alone or with other healthcare-associated pathogens is limited.
Methods: From 2002 to 2006, 498 patients were enrolled into a prospective cohort study at our institution.
Surveillance perirectal, nasal and skin swab samples were obtained upon enrollment. Samples were cultured for the
presence of Candida species, Methicillin Resistant Staphylococcus aureus, Vancomycin Resistant Enterococcus, and
Resistant Gram Negative organisms. Data on demographics, comorbidities, device use, and antibiotic use were also
collected for each subject and analyzed using univariate and multivariate logistic regression.
Results: Factors associated with Candida colonization at admission in univariate analysis included ambulatory
status, a history of Candida colonization and the use of antibiotics prior to enrollment. In multivariate analysis,
ambulatory status (odds ratio; OR = 0.45, 95 % CI: 0.27–0.73) and fluroquinolone use (OR = 3.01, 95 % CI: 1.80–5.01)
were associated with Candida colonization at admission. Factors predicting Candida co-colonization with one or
more MDROs at admission in univariate analysis included, older age, malnutrition, days spent in an ICU in the
2 years prior to enrollment, a history of MRSA colonization, and using antibiotics prior to enrollment. In multivariate
analysis malnutrition (OR = 3.97, 95 % CI: 1.80–8.78) a history of MRSA (OR = 5.51, 95 % CI: 1.89–16.04) and the use
of macrolides (OR = 3.75, 95 % CI: 1.18–11.93) and other antibiotics (OR = 4.94, 95 % CI: 1.52–16.03) were associated
with Candida co-colonization at admission.
Discussion: Antibiotic use was associated with an increased risk of colonization by Candida species alone and in
conjunction with other multidrug-resistant organisms (MDROs). Antibiotic stewardship may be an important
intervention for preventing colonization and subsequent infection by Candida and other MDROs.
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Introduction
In the U.S. healthcare-associated infections (HAI) affect
about 1.7 million individuals and play a role in approxi-
mately 99,000 deaths per year [1, 2]. Candida species are
an important healthcare-associated pathogen with blood-
stream infections resulting from Candida being the fourth
most common cause of hospital acquired bloodstream in-
fection [3]. There is also frequent co-colonization by
Candida and other healthcare-associated pathogens [4]
which has implications for treatment and can result in
various adverse outcomes [5–8].
Colonization precedes infection [9]. Therefore, an un-
derstanding of risk factors for colonization is essential to
devise effective preventive strategies for infection. How-
ever, data on factors predicting colonization by Candida
at admission are limited, with most literature focusing
on colonization in patients with critical illnesses, long
term hospital stays, intensive care unit (ICU) patients or
neonates. We undertook an observational cohort study to
examine risk factors for rectal colonization by Candida
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Table 1 Characteristic totals at hospital admission






Age (avg., yr) 491 56.5 (15.2) 58.2 (15.3) 56.0 (15.1)
Body mass index (avg.) 486 28.6 (8.3) 28.3 (8.5) 28.7 (8.3)
Gender (male) 492 275 (55.9 %%) 52 (18.9 %) 223 (81.1 %)
Gender (female) 492 217 (44.1 %) 41 (18.9 %) 176 (81.1 %)
Ambulatory Status (ambulatory) 492 353 (71.7 %) 53 (15.0 %) 300 (85.0 %)
Alcohol use 492 154 (31.3 %) 34 (22.1 %) 120 (77.9 %)
Surgery 492 69 (14.0 %) 7 (10.1 %) 62 (89.9 %)
Coronary artery disease 492 109 (22.2 %) 25 (22.9 %) 84 (77.1 %)
Chemotherapy 492 62 (12.6 %) 4 (6.5 %) 58 (93.5 %)
Lung Disease 492 62 (12.6 %) 13 (21.0 %) 49 (79.0 %)
Hypertension 492 291 (59.1 %) 56 (19.2 %) 235 (80.8 %)
Immunosuppression 492 192 (39.0 %) 35 (18.2 %) 157 (81.8 %)
Malnutrition 492 77 (15.7 %) 20 (26.0 %) 57 (74.0 %)
Cancer 491 152 (31.0 %) 21 (13.8 %) 131 (86.2 %)
Peripheral vascular disease 492 35 (7.1 %) 10 (28.6 %) 25 (71.4 %)
Renal Failure 492 106 (21.5 %) 15 (14.2 %) 91 (85.8 %)
Steroids 492 172 (35.0 %) 29 (16.9 %) 143 (83.1 %)
Abdominal drain 491 21 (4.3 %) 4 (19.0 %) 17 (81.0 %)
Non-insulin dependent diabetes 492 60 (12.2 %) 13 (21.7 %) 37 (61.7 %)
Insulin-dependent diabetes 491 105 (21.4 %) 19 (18.1 %) 86 (81.9 %)
Foley Catheter 492 116 (23.6 %) 24 (20.7 %) 92 (79.3 %)
Hemodialysis 491 29 (5.9 %) 7 (24.1 %) 22 (75.9 %)
Neutropenia 490 14 (2.9 %) 3 (21.4 %) 11 (78.6 %)
Open wound 486 101 (20.8 %) 20 (19.8 %) 81 (80.2 %)
Transplant 490 111 (22.7 %) 21 (18.9 %) 90 (81.1 %)
Vascular catheter 490 462 (94.5 %) 89 (19.3 %) 373 (80.7 %)
Vent support 492 19 (3.9 %) 8 (42.1 %) 11 (57.9 %)
History of Candida 492 56 (11.4 %) 17 (30.4 %) 39 (69.6 %)
History of MRSAӨ 492 28 (5.7 %) 5 (17.9 %) 23 (82.1 %)
History of VREӨ 492 8 (1.6 %%) 0 (0 %) 8 (100 %)
History of RGNӨ 492 41 (8.3 %) 8 (19.5 %) 33 (80.5 %)
Days in hospital in 2 years. prior (avg,. days) 489 33.8 (108.1) 44.2 (141.6) 31.7(99.6)
Days in ICU in 2 years. prior (avg,. days) 492 1.5 (4.5) 2.1 (4.1) 1.3 (5)
Aminoglycosidesa 492 11 (2.2 %) 3 (27.3 %) 8 (72.7 %)
Carbapenemsa 492 4 (0.8 %) 0 (0 %) 4 (100 %)
1st Gen Cephalosporinsa 492 41 (8.3 %) 5 (12.2 %) 36 (87.8 %)
2nd Gen Cephalosporinsa 492 10 (2.0 %) 1 (10.0 %) 9 (90.0 %)
3rd Gen Cephalosporinsa 492 34 (6.9 %) 7 (20.6 %) 27 (79.4 %)
4th Gen Cephalosporinsa 492 12 (2.4 %) 2 (16.7 %) 10 (83.3 %)
Glycopeptidesa 492 32 (6.5 %) 7 (21.9 %) 25 (78.1 %)
Lincosamidesa 492 23 (4.7 %) 7 (30.4 %) 16 (69.6 %)
Macrolidesa 492 29 (5.9 %) 6 (20.7 %) 23 (79.3 %)
Nitrofuransa 492 5 (1.0 %) 1 (20.0 %) 4 (80.0 %)
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species alone or in conjunction with Methicillin resistant
Staphylococcus aureus (MRSA), Vancomycin resistant En-
terococcus (VRE) and antibiotic resistant Gram-negative
organisms (RGN) at admission to our academic facility.
Methods
Study setting and protocol
The University of Wisconsin hospital is a 592 bed tertiary
care hospital with active solid organ and bone marrow
transplant programs. There are 6 ICUs and the patient
population comes from all over Wisconsin as well as parts
of Illinois and Minnesota. We do not undertake systematic
screening for MRSA, VRE or resistant gram negative bac-
teria. Initiatives to improve hand hygiene have been in
place but began after this study had ended. No other spe-
cific infection control interventions were in place.
From April 2002 to June 2006, 498 patients were en-
rolled into a prospective cohort study at the University of
Wisconsin hospital. A daily census of hospital admissions
was obtained and subjects were randomly selected to be
approached for participation. Patients on the psychiatry
floor or those in the observation unit (anticipated length
of stay < 1 day) were excluded. Consenting patients were
enrolled within 1 day of admission to the hospital and
were followed until hospital discharge. This study was ap-
proved by the institutional review board at our institution.
Surveillance swab samples were obtained from the
subject’s nose, rectal area, underarm area, groin, and if
applicable, open wound sites upon enrollment and once
a week thereafter until discharge. Each rectal area sam-
ple was cultured for the presence of Candida, MRSA,
VRE, and RGN organisms and the nose, underarm and
groin samples were cultured for the presence of MRSA.
Data on baseline demographics, comorbidities and de-
vice use, and pre- and post-hospital admission antibiotic
use were also collected for each subject.
Laboratory methods
To test for the presence of MRSA, the nasal, underarm,
groin, peri-rectal, and wound swabs were inoculated into
tryptic soy broth with 6.5% NaCl for 24 h. Fifty microliters
were then plated onto Mannitol salt agar plates with 4ug/
ml Oxacillin. The plates were then incubated for 48 h and
examined for growth. Gram positive cocci were tested for
catalase and coagulase for identification of S. aureus. All
isolates were also tested for resistance to oxacillin using
Kirby Bauer Disk Diffusion. To test for the presence of
VRE, the rectal swabs were inoculated into bile esculin
broth and incubated for 24 h. Fifty microliters were then
plated onto bile esculin agar with 6ug/ml vancomycin .
Plates were incubated for 48 h and examined for growth.
Gram positive cocci were tested for catalase and pyrrolido-
nyl arylamidase (PYR) for identification of enterococcus. All
isolates were tested for resistance to vancomycin by E-test.
To test for the presence of RGN organisms, the perirectal
swabs were inoculated onto MacConkey agar with 0.5 mg/
L of cefotaxime. Gram negative rods were identified using
oxidase and analytical profile index (API) testing for enteric
and non-enteric bacteria. All isolates were also tested for
resistance using Kirby Bauer methods. To test for the pres-
ence of Candida, the rectal swabs were inoculated onto
Sabouraud’s dextrose agar with chloramphenicol and gen-
tamicin. Each yeast isolate was then identified using API
testing for yeast species.
Definitions
Colonization with Candida was defined as a positive rec-
tal culture for any Candida species. Co-colonization with
Candida was defined as a positive rectal culture for any
Candida species along with a positive rectal culture for
VRE or RGN or a positive rectal, nasal, underarm or
groin culture for MRSA. A history of MRSA or Candida
was defined as having a previous positive culture with
the specified organism.
Statistical methods
Exploratory data analyses and univariate logistic regres-
sion were performed to examine factors associated with
Candida colonization alone and with its co-colonization
with other MDROs. Factors for which the association
Table 1 Characteristic totals at hospital admission (Continued)
Penicillinsa 492 26 (5.3 %) 5 (19.2 %) 21(80.8 %)
Penicillin Combinationsa 492 57 (11.6 %) 19 (33.3 %) 38 (66.7 %)
Fluoroquinolonesa 492 101 (20.5 %) 36 (35.6 %) 65 (64.4 %)
Sulfonamidesa 492 62 (12.6 %) 12 (19.4 %) 50 (80.6 %)
Tetracyclinesa 492 3 (0.6 %) 2 (66.7 %) 1 (33.3 %)
Drugs against mycobacteriaa 492 5 (1.0 %) 1 (20.0 %) 4 (80.0 %)
Other antibioticsb 492 21 (4.3 %) 6 (28.6 %) 15 (71.4 %)
ӨSD standard deviation, MRSA Methicillin resistant Staphylococcus aureus, VRE Vancomycin resistant Enterococcus, RGN antibiotic resistant Gram-negative organisms
All variables are dichotomous, yes vs. no, unless otherwise stated
aAntibiotic use occurred prior to admission to hospital
bOther antibiotics included use of either Metronidazole, Dapsone or Linezolid
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with the outcomes of interest were suggestive (p < 0.10)
were examined for possible retention in multivariate logis-
tic regression. Parsimonious models were constructed
using statistically significant variables and included clinic-
ally relevant factors that did not compromise model fit.
Unadjusted and adjusted odds ratios and corresponding
confidence intervals (CI) were estimated for factors associ-
ated with Candida colonization and its co-colonization
with MDROs. Subjects with missing data were removed
from analysis. Data were analyzed using SAS version 9.4.
Results
The University of Wisconsin hospital is a 592 bed facility
with a patient population that averages 86 % percent
white and 5 % African-American 3 % Hispanic/Latino,
1 % Asian and 5 % other. Four-hundred and ninety-eight
individuals were enrolled in the study and 8 were ultim-
ately removed from multivariate analysis due to missing
data. 275 subjects were male (56 %) and 217 subjects
were female (44 %). The average patient age was 56.5
(15.2) years (Table 1). Nineteen percent of subjects were
colonized with Candida species at baseline, 4.3 % were
Table 2 Univariate odds ratios of Candida colonization at
hospital admission
Characteristic Odds ratio 95 % Confidence
interval
Age (yr) 1.01 0.99–1.03
Body mass index 0.99 0.97 – 1.02
Gender (male vs. female) 1.00 0.63–1.57
Ambulatory Status (ambulatory vs
non-ambulatory)
0.44 0.27 – 0.70
Alcohol use 1.34 0.84–2.15
Surgery 0.44 0.20–1.00
Coronary artery disease 1.38 0.82–2.31
Chemotherapy 0.26 0.09–0.75
Lung Disease 1.16 0.60–2.24
Hypertension 1.06 0.67–1.67
Immunosuppression 0.93 0.58–1.48
Malnutrition 1.67 0.94 – 2.95
Cancer 0.59 0.35–1.01
Peripheral vascular disease 1.80 0.83–3.90
Renal Failure 0.65 0.36–1.19
Steroids 0.81 0.50–1.32
Abdominal drain 1.01 0.33–3.07
Non-insulin dependent diabetes 1.59 0.81–3.13
Insulin-dependent diabetes 0.93 0.53–1.63
Foley Catheter 1.16 0.69–1.95
Hemodialysis 1.39 0.57 – 3.35
Neutropenia 1.17 0.32–4.28
Open wound 1.09 0.63–1.90
Transplant 1.00 0.58–1.71
Vascular catheter 1.37 0.46 – 4.07
Vent support 3.32 1.30–8.50
History of Candida 2.07 1.11–3.84
History of MRSAӨ 0.93 0.34–2.51
History of VREӨ <0.001 <0.001– >999.99
History of RGNӨ 1.04 0.47–2.34
Days in hospital in 2 years.
prior† (days)
1.00 1.00–1.00
Days in ICU in 2 years.
prior† (days)
1.03 0.99–1.07
Aminoglycosidesa 1.63 0.42– 6.26
Carbapenemsa <0.001 <0.001– >999.99
1st Gen Cephalosporinsa 0.57 0.22–1.50
2nd Gen Cephalosporinsa 0.47 0.06–3.76
3rd Gen Cephalosporinsa 1.12 0.47–2.66












Drugs against mycobacteriaa 1.08 0.12–9.72
Other antibioticsb 1.77 0.67–4.68
ӨMRSA =Methicillin resistant Staphylococcus aureus; VRE = Vancomycin
resistant Enterococcus; RGN = antibiotic resistant Gram-negative organisms
All variables are dichotomous, yes vs. no, unless otherwise stated
†Estimate for each additional day in the hospital/ intensive care unit
aAntibiotic use occurred prior to admission to hospital
bOther antibiotics included use of either Metronidazole, Dapsone or Linezolid
Table 3 Multivariate odds ratios of Candida colonization at











Body mass index 0.99 0.96–1.02 0.99 0.97 – 1.02




0.45 0.27–0.73 0.44 0.27 – 0.70
History of
Candida
1.75 0.91–3.37 2.07 1.11–3.84
Fluoroquinolonesa 3.01 1.80–5.01 3.25 1.98–5.32
aAntibiotic use occurred prior to admission to hospital
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Table 4 Characteristic totals for co-colonization at hospital admission
Characteristic N Total (SDӨ,%) With Co-col (SDӨ, %) Without Co-col (SDӨ, %)
Age (avg., yr) 491 56.4 (15.1) 58.9 (17.4) 56.3 (15.0)
Body mass index (avg.) 486 28.6 (8.3) 28.9 (9.2) 28.6 (8.2)
Gender (male) 492 275 (55.9 %) 15 (5.8 %) 260 (94.5 %)
Gender (female) 492 217 (44.1 %) 18 (8.3 %) 199 (91.7 %)
Ambulatory Status (ambulatory) 492 353 (71.7 %) 21(5.9 %) 332 (94.1 %)
Alcohol use 492 154 (31.3 %) 12 (7.8 %) 142 (92.2 %)
Surgery 492 69 (14.0 %) 2 (2.9 %) 67 (97.1 %)
Coronary artery disease 492 109 (22.2 %) 8 (7.3 %) 101 (92.7 %)
Chemotherapy 492 62 (12.6 %) 3 (4.8 %) 59 (95.2 %)
Lung Disease 492 62 (12.6 %) 6 (9.7 %) 56 (90.3 %)
Hypertension 492 291 (59.1 %) 18 (6.2 %) 273 (93.8 %)
Immunosuppression 492 192 (39.0 %) 10 (5.2 %) 182 (94.8 %)
Malnutrition 491 77 (15.7 %) 14 (18.2 %) 63 (81.8 %)
Cancer 491 152 (31.0 %) 9 (5.9 %) 143 (94.1 %)
Peripheral vascular disease 492 35 (7.1 %) 3 (8.6 %) 32 (91.4 %)
Renal Failure 492 106 (21.2 %) 11 (10.4 %) 95 (89.6 %)
Steroids 492 172 (35.0 %) 9 (5.2 %) 163 (94.8 %)
Abdominal drain 491 21 (4.3 %) 1 (4.8 %) 20 (95.2 %)
Non-insulin dependent diabetes 492 50 (10.2 %) 4 (8.0 %) 46 (92.0 %)
Insulin-dependent diabetes 491 105 (21.4 %) 8 (7.6 %) 97 (92.4 %)
Foley Catheter 492 116 (24.2 %) 12 (10.3 %) 104 (89.7 %)
Hemodialysis 490 29 (5.9 %) 3 (10.3 %) 26 (89.7 %)
Neutropenia 490 14 (2.9 %) 1 (7.1 %) 13 (92.9 %)
Open wound 486 101 (20.8 %) 10 (9.9 %) 91 (90.1 %)
Surgical wound 490 76 (15.5 %) 6 (7.9 %) 70 (92.1 %)
Transplant 490 111 (22.7 %) 4 (3.6 %) 107 (96.4 %)
Vascular catheter 489 462 (94.5 %) 31 (6.7 %) 431 (93.3 %)
Vent support 492 19 (3.9 %) 2 (10.5 %) 17 (89.5 %)
History of Candida 492 56 (11.4 %) 5 (8.9 %) 51 (91.1 %)
History of MRSAӨ 492 28 (5.7 %) 8 (28.6 %) 20 (71.4 %)
History of VREӨ 492 8 (1.6 %) 1 (12.5 %) 7 (87.5 %)
History of GNӨ 492 41 (8.3 %) 4 (9.8 %) 37 (90.2 %)
Days in hospital in 2 years.
prior to admit (avg., days)
489 34.1 (108.8) 34.1 (40.5) 34.1 (112.1)
Days in ICU in 2 years.
prior to admit (avg., days)
492 1.5 (4.9) 4.5 (9.6) 1.3 (4.3)
Aminoglycosidesa 492 11 (2.2 %) 1 (9.1 %) 10 (90.9 %)
Carbapenemsa 492 4 (0.8 %) 2 (50.0 %) 2 (50.0 %)
1st Gen Cephalosporinsa 492 41 (8.3 %) 3 (7.3 %) 38 (92.7 %)
3rd Gen Cephalosporinsa 492 34 (6.9 %) 5 (14.7 %) 29 (85.3 %)
4th Gen Caphalosporinsa 492 12 (2.4 %) 1 (8.3 %) 11 (91.7 %)
Glycopeptides 492 32 (6.5 %) 5 (15.6 %) 27 (84.4 %)
Lincosamidesa 492 23 (4.7 %) 1 (4.3 %) 22 (95.7 %)
Macrolidesa 492 29 (5.9 %) 5 (17.2 %) 24 (82.8 %)
Penicillinsa 492 26 (5.3 %) 4 (15.4 %) 22 (84.6 %)
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colonized with VRE, 1.8 % were colonized with RGN,
1.4 % were colonized with MRSA, and 8.6 % were colo-
nized with multiple organisms.
In univariate analysis, a patient’s need for ventilator sup-
port (OR = 3.32, 95 % CI: 1.30–8.50), history of Candida
colonization (OR = 2.07, 95 % CI: 1.11–3.84), and use of
penicillin combinations (OR = 2.44, 95 % CI: 1.33–4.47)
and fluoroquinolone use (OR = 3.25, 95 % CI: 1.98–5.32)
prior to admission were significantly associated with higher
odds of being colonized by Candida species only, at the
time of hospital admission (Table 2). A patient’s ambula-
tory status (OR = 0.44, 95 % CI: 0.27–0.70) and chemother-
apy use (OR = 0.26, 95 % CI: 0.09–0.75) were associated
with lower odds of colonization by Candida species.
In multivariate analysis, adjusting for age, and other
factors included in the model patients who could ambu-
late had 55 % lower odds of being colonized with only
Candida at admission (OR = 0.45, 95 % CI: 0.27–0.73).
Patients who used quinolones prior to hospital admis-
sion had three times greater odds of being colonized
with Candida at admission to the hospital (OR = 3.01,
95 % CI: 1.80–5.014) (Table 3).
We examined factors for co-colonization by Candida
species and one or more of the other organisms of interest
in this study (Table 4). In univariate analysis, malnutrition
(OR = 4.62, 95 % CI: 2.21–9.68), history of MRSA
colonization (OR = 7.03, 95 % CI: 2.82–17.52), days spent
in an ICU in the two years prior to their present hospital
admission (OR = 1.07, 95 % CI: 1.03–1.12), and use of car-
bapenems (OR = 14.74, 95 % CI: 2.01–108.22), glycopep-
tides (OR = 2.86, 95 % CI: 1.02–7.99), macrolides (OR =
3.24, 95 % CI: 1.15–9.13), drugs against Mycobacteria
(OR = 9.81, 95 % CI: 1.58–60.88) and either metronida-
zole, dapsone, or linezolid (OR = 4.94, 95 % CI: 1.69–
14.48) were significantly associated with a higher odds of
being co-colonized with Candida and another organism at
the time of hospital admission (Table 5).
In multivariate analysis, adjusting for age, and other
factors included in the model, we found that, at admis-
sion, malnourished individuals had a four-fold greater
odds of being co-colonized (OR = 3.97, 95 % CI: 1.80–
8.78) and individuals with a history of MRSA had over a
five-fold greater odds of being co-colonized (OR = 5.51,
95 % CI: 1.89–16.04). Individuals who used macrolides
prior to admission had almost a four-fold greater odds
of being co-colonized (OR = 3.75, 95 % CI: 1.18–11.93)
and individuals who used either metronidazole, dapsone,
or linezolid had a five-fold greater odds of being co-
colonized (OR = 4.94, 95 % CI: 1.52–16.03) (Table 6).
Discussion
Infection by Candida species in hospitalized patients is as-
sociated with considerable morbidity and mortality. Pre-
vention is essential but a better understanding of the
factors that predict colonization by Candida species is
needed. Our study expands the current literature in this
area. We identified a number of factors that predicted
colonization by Candida species alone or in conjunction
with other MDROs. Specifically, we found that individuals
who were able to ambulate were less likely to be colonized
with Candida species at enrollment and those using Fluor-
oquinolones prior to admission were more likely to be col-
onized with Candida species at enrollment. Additionally,
we identified several factors that predicted co-colonization
with other MDROs at enrollment. These included malnu-
trition, a history of MRSA, and the use of Macrolides or
the use of either Metronidazole, Dapsone, or Linezolid
prior to hospital admission.
We found that subjects who could ambulate as opposed
to those who could not were about 50 % less likely to be
colonized with Candida at enrollment. These individuals
were more likely to have been mobile, and not been con-
fined to a hospital or long-term care facility. Our findings
are consistent with studies that have shown that individ-
uals who can ambulate are less likely to develop infections
[10–13], one study even suggested that patients who are
admitted to long-term care facilities ambulate more fre-
quently as a form of infection prevention [14].
We also found that subjects with a history of Candida
colonization were more likely to be colonized with
Candida at admission than those without this history.
Our findings are in keeping with previous studies which
reported that colonization with Candida species may be
prolonged [15].
Table 4 Characteristic totals for co-colonization at hospital admission (Continued)
Penicillin Combinationsa 492 57 (11.6 %) 5 (8.8 %) 52 (91.2)
Fluoroquinolonesa 492 101 (20.5 %) 10 (9.9 %) 91 (90.1 %)
Sulfonamidesa 492 62 (12.6 %) 1 (1.6 %) 61 (98.4 %)
Drugs against mycobacteriaa 492 5 (1.0 %) 2 (40.0 %) 3 (60.0 %)
Other antibioticsb 492 21 (4.3 %) 5 (23.8 %) 16 (76.2 %)
ӨSD standard deviation, MRSA Methicillin resistant Staphylococcus aureus, VRE Vancomycin resistant Enterococcus, RGN antibiotic resistant Gram-negative organisms
All variables are dichotomous, yes vs. no, unless otherwise stated
aAntibiotic use occurred prior to admission to hospital
bOther antibiotics included use of either Metronidazole, Dapsone or Linezolid
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Additionally we identified factors that were associated
with an increase in the risk of co-colonization by Candida
and at least one other MDRO. Subjects with malnutrition
showed an increased risk of being co-colonized at base-
line. Malnutrition can impair an individual’s immunity
and cause immune dysfunction, thus affecting the body’s
ability to fight infection [16, 17]. Accordingly, this impair-
ment of an individual’s immune system as a result of their
malnutrition could be the driving force associating malnu-
trition and a higher likelihood of co-colonization.
Having a history of MRSA colonization was also indica-
tive of being co-colonized at baseline. Previous studies
have shown an association between having a history of
MRSA and having a positive MRSA screening sample at
hospital admission [18] as well as an association between
having a history of Staphylococcus colonization and devel-
oping a surgical site infection [19]. This suggests then that
having a history of MRSA could be a predictor of baseline
colonization with not only MRSA but other organisms as
well, including Candida. Colonization with MRSA can also
be indicative of a previous hospitalization or previous use
Table 5 Univariate odds ratios of Candida co-colonization at
hospital admission
Characteristic Odds ratio 95 % Confidence
interval
Age (yr) 1.01 0.99–1.04
Body mass index 1.01 0.97 – 1.05




0.67 0.32 – 1.40
Alcohol use 1.28 0.61–2.66
Surgery 0.38 0.09–1.62
Coronary artery disease 1.13 0.50–2.59
Chemotherapy 0.68 0.20–2.29





Peripheral vascular disease 1.34 0.39–4.61
Renal Failure 1.92 0.90–4.09
Steroids 0.68 0.31–1.50
Abdominal drain 0.68 0.09–5.26
Non-insulin dependent diabetes 1.24 0.42–3.68
Insulin-dependent diabetes 1.19 0.52–2.72
Foley Catheter 1.95 0.93–4.10
Hemodialysis 1.72 0.49 – 6.02
Neutropenia 1.07 0.14 – 8.42
Open wound 1.73 0.80–3.76
Surgical wound 1.23 0.49 – 3.09
Transplant 0.47 0.16–1.37
Vascular catheter 0.90 0.20 – 3.97
Vent support 1.68 0.37–7.59
History of Candida 1.43 0.53–3.86
History of MRSAӨ 7.03 2.82 – 17.52
History of VREӨ 2.02 0.24 – 16.91
History of GNӨ 1.57 0.53–4.72
Days in hospital in 2 years.
prior to admit† (days)
1.00 1.00–1.00
Days in ICU in 2 years.




1st Gen Cephalosporinsa 1.11 0.32–3.80
3rd Gen Cephalosporinsa 2.65 0.95–7.37
4th Gen Caphalosporinsa 1.27 0.16 – 10.17
Glycopeptides 2.86 1.02 – 7.99
Lincosamidesa 0.62 0.08–4.75




Penicillin Combinationsa 1.40 0.52–3.78
Fluoroquinolonesa 1.76 0.81–3.82
Sulfonamidesa 0.20 0.03–1.52
Drugs against mycobacteriaa 9.81 1.58 – 60.88
Other antibioticsb 4.94 1.69–14.48
ӨMRSA Methicillin resistant Staphylococcus aureus, VRE Vancomycin resistant
Enterococcus, RGN antibiotic resistant Gram-negative organisms All variables
are dichotomous, yes vs. no, unless otherwise stated
†Estimate for each additional day in the hospital/ intensive care unit
aAntibiotic use occurred prior to admission to hospital
bOther antibiotics included use of either Metronidazole, Dapsone or Linezolid
Table 6 Multivariate odds ratios of Candida co-colonization at











Age (yr) 1.03 1.01–1.06 1.01 0.99 - 1.04
Malnutrition 3.97 1.80–8.78 4.62 2.21–9.68
History of MRSA 5.51 1.89–16.04 7.03 2.82 – 17.52
Days in ICU in
2 years prior to
admission† (days)
1.05 1.00–1.11 1.07 1.03–1.12
Macrolidesa 3.75 1.18v11.93 3.24 1.15–9.13
Other antibioticsb 4.94 1.52–16.03 4.94 1.69–14.48
†Estimate for each additional day in the intensive care unit
aAntibiotic use occurred prior to admission to hospital
bOther antibiotics included use of either Metronidazole, Dapsone or Linezolid
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of antibiotics; these variables have been shown to be asso-
ciated with colonization and therefore may also be mediat-
ing this relationship [20].
The use of certain antibiotics was implicated with a
higher likelihood of colonization and co-colonization. Pre-
vious studies have also highlighted the association existing
between antibiotic use and Candida colonization [21–25].
It has been found that the use of antibiotics with broad-
spectrum activity were associated with higher levels of C.
albicans colonization and accordingly our study also found
that subjects taking certain antibiotics prior to admission
were more likely to be colonized and co-colonized at en-
rollment [21]. More specifically, we have observed that the
use of quinolones prior to hospitalization was associ-
ated with an increase in a subject’s likelihood of being
colonized with Candida at baseline and the use of
macrolides and either metronidazole, dapsone or linez-
olid prior to hospitalization was associated with an in-
crease in a subject’s likelihood of being co-colonized
with Candida and another organism at baseline. It has
been suggested that individuals taking antibiotics were
more likely have a reduction in intestinal bacteria,
allowing Candida to opportunistically grow, thus result-
ing in an increase in intestinal Candida counts [22]
which would support this observed association. Informa-
tion on the the duration of antibiotic exposure and
whether or not antibiotics were appropriately utilized by
each subject was unavailable in this study but would be an
important point of interest for future studies. In this regard
however, our study has highlighted the possible antibiotics
that should be more closely monitored in future studies
and in a clinical setting when prescribed to patients.
A limitation of this study was its small sample size,
which will restrict the power of our associations. We also
lacked information on length of use and date of last dose
for pre-admission antibiotics, which limited our ability to
fully describe the relationship between these drugs and
colonization. Additionally, we repeated surveillance test-
ing no more frequently than every 3 days, so a positive test
after the admission test was negative was a priori defined
as acquisition. It is possible that our admission testing re-
sulted in false negatives, however we followed procedure
similar to that of most studies that have evaluated acquisi-
tion. Finally, we lacked information on possible pre- and
post-admission antifungal use by the subjects in our data-
set and cannot make any assertions about the role these
drugs might play on the outcome of colonization and co-
colonization. The use of antifungals however is an import-
ant factor to analyze in future studies.
Conclusion
Our study has shown that ambulatory status, malnutri-
tion, a history of MRSA colonization, and antibiotic use
prior to admission were significant risk factors for
Candida colonization and co-colonization at hospital ad-
mission. These risk factors are important indicators of
colonization to be examined in patients at hospital admis-
sion so as to better anticipate and prevent colonization
and co-colonization with Candida species and MRSA,
VRE and RGN organisms. Also, given that antibiotic use
is a directly mutable variable, interventions should be di-
rected at promoting appropriate antibiotic administration
and utilization. More research should now be performed
to more completely understand the mechanisms by which
these risk factors can affect an individual’s colonization
status so as to improve prediction and prevention proce-
dures for colonization and ultimately protect patients
from avoidable infection.
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